Marietta Wealth Management LLC Boosts Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Marietta Wealth Management LLC increased its stake in Thermo Fisher Scientific Inc. by 6.5% in the second quarter, acquiring a total of 16,399 shares worth approximately $6.65 million.
• Several analysts have raised their price targets for Thermo Fisher Scientific, with UBS Group setting a new target of $500 and Raymond James increasing theirs to $535, reflecting positive market sentiment.
• The company recently declared a quarterly dividend of $0.43 per share, signaling continued financial stability, with an annualized yield of 0.3% and a low payout ratio of 9.95%.

Marietta Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,399 shares of the medical research company's stock after buying an additional 1,007 shares during the quarter. Marietta Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $6,649,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of TMO. Brighton Jones LLC boosted its stake in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after buying an additional 988 shares during the period. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Vest Financial LLC lifted its position in shares of Thermo Fisher Scientific by 73.4% during the first quarter. Vest Financial LLC now owns 3,188 shares of the medical research company's stock worth $1,586,000 after purchasing an additional 1,349 shares during the last quarter. Signal Advisors Wealth LLC lifted its position in shares of Thermo Fisher Scientific by 7.2% during the first quarter. Signal Advisors Wealth LLC now owns 1,297 shares of the medical research company's stock worth $646,000 after purchasing an additional 87 shares during the last quarter. Finally, Eagle Rock Investment Company LLC lifted its position in shares of Thermo Fisher Scientific by 0.3% during the first quarter. Eagle Rock Investment Company LLC now owns 7,489 shares of the medical research company's stock worth $3,727,000 after purchasing an additional 26 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. UBS Group lifted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Raymond James Financial restated an "outperform" rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. HSBC restated a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $585.37.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the company's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $56,937,881. This represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,066 shares of company stock worth $14,182,963. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $543.88 on Friday. The company has a market capitalization of $205.37 billion, a PE ratio of 31.46, a P/E/G ratio of 2.95 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a 50-day simple moving average of $482.58 and a two-hundred day simple moving average of $447.27. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the firm earned $5.37 earnings per share. The company's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.